Skip to content

CVKD

Cadrenal Therapeutics, Inc. Common Stock

NASDAQ · Healthcare · Biotechnology · US

$1.22
−4.69%
Ask drillr

Income statement

MetricTTM2025202420232022
Revenue
Total Revenue
Cost of Revenue956.001.3K
Gross Profit(956.00)(1.3K)
Operating Expenses
R&D Expense2.8M4.1M4.2M4.1M392.9K
SG&A Expense8.8M9.4M6.8M3.5M2.3M
General & Admin Expense8.8M9.4M6.8M3.5M
Selling & Marketing Expense
Other Expenses2.0K6.9K1.9K2.0K
Total Operating Expenses11.7M13.5M11.0M7.6M2.7M
Cost and Expenses11.7M13.5M11.0M7.6M2.7M
Operating Income (EBIT)(11.7M)(13.5M)(11.0M)(7.6M)(2.7M)
Non-Operating
Interest Income109.9K223.8K309.3K249.1K
Interest Expense17.1K107.1K
Net Interest Income109.9K223.8K309.3K232.0K(107.1K)
Other Non-Op Income/Expense109.9K223.8K309.3K(724.2K)(4.0M)
Non-Operating Income (excl Interest)(92.1K)(223.8K)(309.3K)707.1K3.9M
EBT (Pre-Tax Income)(11.5M)(13.2M)(10.7M)(8.4M)(6.7M)
Income Tax Expense
Bottom Line
Net Income(11.5M)(13.2M)(10.7M)(8.4M)(6.7M)
Earnings from Cont. Ops(11.5M)(13.2M)(10.7M)(8.4M)(6.7M)
Earnings from Discont. Ops
Bottom Line Net Income(11.5M)(13.2M)(10.7M)(8.4M)(6.7M)
Per Share
Basic EPS($4.90)($6.64)($8.73)($9.63)($8.66)
Diluted EPS($4.90)($6.64)($8.73)($9.63)($8.66)
Revenue Per Share$0.00$0.00$0.00$0.00$0.00
Shares
Basic Shares Outstanding2.9M2.0M1.2M868183775638
Diluted Shares Outstanding2.9M2.0M1.2M868183775638
Profitability Metrics
EBITDA(11.6M)(13.2M)(10.6M)(8.3M)(6.6M)
D&A2.0K6.9K1.9K2.0K1.3K
EBIT(11.6M)(13.2M)(10.7M)(8.3M)(6.6M)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026